While most of the world was focused on the shifting political tides of 2025 and 2026, a legal storm was brewing in the Southern District of New York that has forever changed the landscape of healthcare compliance. The case is United States ex rel. Bassan v. Omnicare, Inc., 1:2015cv04179 (S.D.N.Y. 2019) and it recently concluded with one of the largest jury verdicts in the history of the False Claims Act (FCA).
On July 7, 2025, a federal court entered a staggering $949 million judgment against Omnicare, the nation’s largest provider of pharmacy services to long-term care facilities, and its parent company, CVS Health Corporation.
This wasn’t just a win for the government; it was a vindication for a single pharmacist from New Mexico who refused to ignore a system that he believed put millions of elderly patients at risk.
The Background: The Pharmacist Who Knew Too Much
The story began in 2015 when Uri Bassan, a pharmacist-in-charge at an Omnicare location in Albuquerque, filed a qui tam lawsuit. Bassan had noticed a disturbing pattern: Omnicare was allegedly dispensing powerful prescription drugs to residents of assisted living facilities without valid, current prescriptions.
In the world of long-term care, “valid” isn’t a suggestion—it’s a life-saving requirement. Federal law prohibits the reimbursement of drugs unless they are supported by a prescription that hasn’t expired or run out of refills. Bassan alleged that Omnicare was using “cycle-fill” or “rollover” dispensing, effectively putting drug delivery on autopilot. When a prescription expired, the system would allegedly assign a new number and keep the drugs flowing, often without a doctor ever reviewing the patient’s chart.
In 2019, the U.S. Department of Justice intervened in the case, adding its significant resources and broadening the investigation to include Omnicare’s parent company, CVS Health, which had acquired the pharmacy giant in 2015.
The Trial: 3.3 Million False Claims
The trial, which took place in April 2025 before Judge Colleen McMahon, was a marathon of data. The government and Bassan presented evidence that between 2010 and 2018, Omnicare submitted claims for reimbursement to Medicare, Medicaid, and TRICARE for drugs that were essentially dispensed illegally.
The Jury’s Findings:
- Scale of Fraud: The jury found Omnicare liable for submitting 3,341,032 false claims.
- Damages: They assessed actual damages (the amount the government paid out) at $135.6 million.
- CVS Liability: Crucially, the jury found that CVS Health “caused” over 1 million of those false claims to be submitted after its acquisition of Omnicare.
The Holding: Treble Damages and “Nuclear” Penalties
Under the False Claims Act, the “price of admission” for fraud is high. The court is required to treble (triple) the damages and add civil penalties for every single false claim.
- Treble Damages: The $135.6 million in actual damages was automatically tripled to $406.8 million.
- Statutory Penalties: This is where the case became truly historic. If the judge had applied the standard FCA penalty (roughly $13,000 to $27,000 per claim) to 3.3 million claims, the penalty would have exceeded $26 billion—enough to bankrupt almost any corporation on earth.
Recognizing that a $26 billion fine might violate the Eighth Amendment’s Excessive Fines Clause, the government exercised “prosecutorial discretion” and asked for a much lower (but still massive) penalty. In her July 2025 ruling, Judge McMahon ordered:
- $542 million in civil penalties against Omnicare.
- $164.8 million of that total to be held “jointly and severally” against CVS Health.
Final Judgment Total: $948.8 Million.
The Reasoning: Why the Parent Company Was on the Hook
One of the most significant aspects of the Bassan case is the liability of CVS Health Corp. CVS argued that it was merely a holding company and shouldn’t be held responsible for the day-to-day dispensing errors of its subsidiary, Omnicare.
Judge McMahon rejected this “passive parent” defense. The evidence showed that CVS was aware of the dispensing issues—through internal audits and its own compliance structure—but allowed Omnicare to “dilly-dally” for years without fixing the problem. The court ruled this was “knowing ratification.” If a parent company has the power and the obligation to correct a fraud and chooses not to for business reasons, they are just as liable as the subsidiary.
Why Bassan v. Omnicare is a “Big Deal”
This case is currently the “North Star” for False Claims Act litigation in 2026 for three reasons:
- The Death of the “Passive Parent” Defense
For years, large healthcare conglomerates have used their complex corporate structures to shield themselves from the mistakes of their subsidiaries. Bassan proves that a Corporate Integrity Agreement (CIA) is not just a piece of paper; it creates a direct line of liability to the very top of the organization.
- The Constitutional Battle Over Penalties
CVS is currently appealing the $949 million judgment to the Second Circuit, arguing that even a “reduced” penalty of $542 million is unconstitutionally excessive. This is part of a broader trend where companies are trying to use the Supreme Court’s recent focus on “proportionality” to weaken the FCA. The outcome of this appeal will define how “scary” the FCA remains for large-scale fraudsters.
- The Power of a Single Relator
Uri Bassan’s share of this recovery is expected to be life-changing. Because the government intervened, he is entitled to between 15% and 25% of the recovery. On a nearly $950 million judgment, his “relator’s share” could be upwards of $140 million to $200 million. His story serves as a massive incentive for other pharmacists and medical professionals to step forward.
The “Cycle-Fill” Trap: How Automation Replaced Medical Judgment
To understand why the jury was so moved by Bassan’s evidence, one must look at the “Cycle-Fill” system Omnicare implemented. In a standard pharmacy, a pharmacist waits for a new prescription or a refill request. At Omnicare, the process was allegedly flipped. The pharmacy’s computer system was designed to automatically “roll over” prescriptions for chronic medications to ensure a steady “cycle” of delivery.
The problem, as Bassan testified, was that this automation became a substitute for doctor oversight. When a prescription reached its legal limit of refills, the system wouldn’t stop; instead, it would allegedly generate a “dummy” prescription number or link the dispense to a generic, non-existent order. This allowed Omnicare to bill the government for millions of doses that—on paper—had no legal authorization. For the jury, this wasn’t just a technical glitch; it was a deliberate choice to prioritize “efficiency” (and the resulting billing stream) over the fundamental legal requirement that a doctor must authorize every pill dispensed to a senior citizen.
Conclusion
The Bassan v. Omnicare verdict is a warning shot to the entire pharmaceutical industry. It demonstrates that “business as usual”—even when automated—can become a billion-dollar liability if it ignores the fundamental safety requirements of the law.
As the case moves through the appeals process in 2026, it remains the ultimate example of how one person with a conscience and a good lawyer can take down a titan. In the end, the government isn’t just paying for pills; it’s paying for the professional judgment of a pharmacist. When that judgment is replaced by an algorithm, the price tag is $949 million.